Literature DB >> 15247174

Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

L-H Wang1, X-C Fang, G-Z Pan.   

Abstract

BACKGROUND AND AIMS: The incidence of irritable bowel syndrome (IBS) or functional bowel disorders (FBD) after bacillary dysentery (BD) has not been extensively evaluated, and little is known of the pathogenesis of post-infective (PI) IBS. Therefore, we investigated the incidence of IBS and FBD in a Chinese patient population who had recovered from BD. To further elucidate its pathogenesis, neuroimmunological changes, including interleukins (IL), mast cells, neuropeptides, and the relationship between mast cells and intestinal nerves, were investigated.
METHODS: A cohort study of 295 patients who had recovered from BD (shigella identified from stool in 71.4%) and 243 control subjects consisting of patient siblings or spouses who had not been infected with BD were included in the study. All subjects were followed up using questionnaires for 1-2 years to explore the incidence of FBD and IBS, as defined by the Rome II criteria. In 56 cases of IBS (PI and non-PI) from another source, the number of mast cells in biopsy specimens from the intestinal mucosa were stained with antitryptase antibody and counted under light microscopy. Also, the relationship of mast cells to neurone specific enolase (NSE), substance P (SP), 5-hydroxytryptamine (5-HT), or calcitonin gene related peptide positive nerve fibres was observed using double staining with alcian blue and neuropeptide antibodies. In 30 cases of IBS (PI-IBS, n = 15) taken at random from the 56 cases, expression of interleukin (IL)-1alpha, IL-1beta, and IL-1 receptor antagonist (IL-1ra) mRNAs in intestinal mucosa were identified using reverse transcription-polymerase chain reaction. The above results were compared with 12 non-IBS controls.
RESULTS: In the BD infected cohort, the incidences of FBD and IBS were 22.4% and 8.1% (in total)-10.2% (among those in who shigella were identified) respectively, which were significantly higher (p<0.01) than the incidences of FBD (7.4%) and IBS (0.8%) in the control cohort. A longer duration of diarrhoea (>or=7 days) was associated with a higher risk of developing FBD (odds ratio 3.49 (95% confidence interval 1.71-7.13)). Expression of IL-1beta mRNA in terminal ileum and rectosigmoid mucosa was significantly higher in PI-IBS patients (p<0.01). The number of mast cells in the terminal ileum mucosa in PI-IBS (11.19 (2.83)) and non-PI-IBS patients (10.78 (1.23)) was significantly increased compared with that (6.05 (0.51)) in control subjects (p<0.01). Also, in the terminal ileum and rectosigmoid mucosa of IBS patients, the density of NSE, SP, and 5-HT positively stained nerve fibres increased (p<0.05) and appeared in clusters, surrounding an increased number of mast cells (p<0.01 compared with controls).
CONCLUSIONS: BD is a causative factor in PI-IBS. The immune and nervous system may both play important roles in the pathogenesis of PI-IBS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247174      PMCID: PMC1774156          DOI: 10.1136/gut.2003.021154

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Activation of the mucosal immune system in irritable bowel syndrome.

Authors:  Vinton S Chadwick; Wangxue Chen; Dairu Shu; Barbara Paulus; Peter Bethwaite; Andy Tie; Ian Wilson
Journal:  Gastroenterology       Date:  2002-06       Impact factor: 22.682

2.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

3.  Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling.

Authors:  G Pan; S Lu; M Ke; S Han; H Guo; X Fang
Journal:  Chin Med J (Engl)       Date:  2000-01       Impact factor: 2.628

4.  Interleukin-1 beta inhibits the intestinal transport of [14C] 3-O-methylglucose in the rat.

Authors:  S I Kreydiyyeh; J J Haddad; B S Garabedian
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

5.  Impaired sympathetic nerve function in the inflamed rat intestine.

Authors:  M G Swain; P A Blennerhassett; S M Collins
Journal:  Gastroenterology       Date:  1991-03       Impact factor: 22.682

6.  Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue.

Authors:  S H Ferreira; B B Lorenzetti; A F Bristow; S Poole
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

7.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

8.  Cosensitivity of vagal mucosal afferents to histamine and 5-HT in the rat jejunum.

Authors:  M E Kreis; W Jiang; A J Kirkup; D Grundy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-09       Impact factor: 4.052

Review 9.  Neuropathophysiology of irritable bowel syndrome.

Authors:  Jackie D Wood
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062

10.  Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome.

Authors:  K-A Gwee; S M Collins; N W Read; A Rajnakova; Y Deng; J C Graham; M W McKendrick; S M Moochhala
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

View more
  99 in total

1.  East meets West: infection, nerves, and mast cells in the irritable bowel syndrome.

Authors:  S M Collins; G Barbara
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

2.  Mast cells and intestinal motility disorders (mastocytic enteritis/colitis).

Authors:  David F Schaeffer; Richard Kirsch; Robert H Riddell
Journal:  Dig Dis Sci       Date:  2012-05       Impact factor: 3.199

Review 3.  Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?

Authors:  Laura Noddin; Michael Callahan; Brian E Lacy
Journal:  MedGenMed       Date:  2005-08-29

Review 4.  Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions.

Authors:  Lena Ohman; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01-26       Impact factor: 46.802

Review 5.  Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.

Authors:  Uday C Ghoshal; Kok-Ann Gwee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

6.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 7.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

8.  MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.

Authors:  QiQi Zhou; Wiley W Souba; Carlo M Croce; G Nicholas Verne
Journal:  Gut       Date:  2009-12-01       Impact factor: 23.059

9.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

10.  Irritable bowel syndrome: diagnosis and pathogenesis.

Authors:  Magdy El-Salhy
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.